Ownership
Private
Employees
~50
Stage
Phase 2
Modalities
Small molecule

Genhouse Bio General Information

Clinical stage company with multiple programs including KRAS G12C inhibitor GH35, SHP2 inhibitor GH21, ERK1/2 inhibitor GH55, and KIF18A inhibitor GH2616. Clinical collaboration with AstraZeneca for GH21 + osimertinib combination in NSCLC.

Contact Information

Website
Primary Industry
Biotech
Corporate Office
Suzhou,
China

Drug Pipeline

GH21
Phase 2
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 2
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum
Drug Asset 3
Phase X
Indications: Lorem ipsum dolor sit
Modality: Lorem ipsum

For full access to Genhouse Bio's pipeline data

Book a demo

Key Partnerships

AstraZeneca, HUYABIO

Need more data on over 80,000 life science companies, including over 1200 biotechs?

Book a demo

Genhouse Bio Funding

No funding data available

Early Stage VC (Series A)04-Jun-2020$38MCompletedPhase 1
Seed Round12-Feb-2019$8.5MCompletedStartup

Interested in comprehensive profile data?

We'll help you find what you need

Learn more
To view Genhouse Bio's complete valuation and funding history, request access »

Genhouse Bio Investors

Legend Star
Investor Type: Venture Capital
Holding: Minority
Qian Dao Fund
Investor Type: Venture Capital
Holding: Minority
LC Ventures
Investor Type: Venture Capital
Holding: Minority
Investor Name
Investor Type
Holding
Investor Name
Investor Type
Holding
You're viewing 3 of 6 investors. Get the full list »